Drug Prices, Biosimilars, Gene Therapies Will Be 2020 Trends

As far as overall industry themes expected in 2020, drug pricing will remain a hot topic. Following a year in which FDA approvals of biosimilars hit double digits for the first time with 10, it’s not much of a surprise that many sources foresee a continued focus on these products in 2020. Last year also saw the launches of the first oncology biosimilars, and multiple competitors to three top-selling drugs — Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab) — could see aggressive payer contracting efforts to try to bring down prices in multiple oncology indications (RSP 1/20, p. 1). And the approval and subsequent launch of Zolgensma (onasemnogene abeparvovec-xioi), the first product in the United States to top $1 million, has put the spotlight on other gene therapies coming down the pike.

“Pricing will remain a key focal point for 2020, but one thing to keep an eye on specifically within this realm will be pricing of biosimilars,” says Andrew Cournoyer, R.Ph., vice president, director, access experience team at Precision for Value. “A number of key biosimilar launches are expected in 2020.…There are expectations that biosimilars will help to lower specialty drug costs. The extent of potential savings will be interesting to watch but could be realized from a couple of avenues.

© 2024 MMIT
Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

businessman-viewing-news-update-journalism-headline-on-a-laptop
May 9

News Briefs: Fresenius Kabi Launches First Actemra Biosimilar

READ MORE
patient-taking-pills
May 9

Established TKI Gains New Indication to Treat Aggressive Cancer

READ MORE
doctor-holding-patient-hand
May 9

One Repatha Presentation Will Be Discontinued Next Month, Another in 2025

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today